Form 4: Beam Therapeutics CEO John M. Evans Sells 60,000 Shares

Beam Therapeutics CEO John M. Evans sold 60,000 shares of common stock on September 30, 2024, at a weighted average price of $24.6004.

Summary

• John M. Evans, CEO of Beam Therapeutics Inc., reported a change in beneficial ownership of the company's stock.
• On September 30, 2024, Evans sold 60,000 shares of common stock at a weighted average price of $24.6004.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 29, 2023.
• The price per share ranged from $24.26 to $25.24.
• Following the transaction, Evans directly owns 938,659 shares of Beam Therapeutics Inc.
• Evans also indirectly owns 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust.
• Evans acquired 316 shares under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, as it simply reports facts.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on insider information.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates